Estudo terapêutico aberto com sulfato de aminosidine na leishmaniose mucosa causada for Leishmania (viannia) braziliensis

Abstract

From September to November 1994, 21 patients with active mucosal leishmaniasis were treated with aminosidine sulphate I6mg/kg/day by intramuscular injection for 20 days. They were principally adult male agricultural workers. Thirteen patients had not received specific treatment and eight had failed to respond to Glucantime® therapy. Diagnosis was based on clinical and epidemiological observations, a search for the parasite, leishmanin skin sensitivity and indirect fluorescent antibody serological tests. Sixty seven percent of patients had Leishmania parasites isolated from inoculated hamsters or visualized in imprints or histopathological sections. The mean follow-up period was 12.6 months. All patients completed treatment. Side effects were pain at the injection site (86%), mild proteinuria (24%), elevated serum creatinine (5%) and subclinical hearing loss in one of two patients who did audiometric tests. Clinical cure was achieved in 48% and the accumulated relapse rate was 29% (4/14).

ARTIGOS

Estudo terapêutico aberto com sulfato de aminosidine na leishmaniose mucosa causada for Leishmania (viannia) braziliensis

Gustavo A.S. Romero; Hélio A. Lessa; Vanize O. Macêdo; Edgar M. Carvalho; Aldina Barrai; Albino V. Magalhães; Maria G.O. Orge; Maria VA. Abreu; Philip D. Marsden

Endereço para correspondência

------------

RESUMO

No período de setembro a novembro de 1994 foram tratados 21 pacientes com leishmaniose mucosa ativa, predominantemente adultos lavradores do sexo masculino, com sulfato de aminosidine intramuscular, I6mg/kg/dia por 20 dias. Treze pacientes eram virgens de tratamento e 8 haviam sido tratados sem sucesso com Glucantime®". O diagnóstico baseou-se inicialmente em crítêrios epidemiolôgicos, clínicos e nos resultados da intrademoireação de Montenegro e a imunofluorescência indireta para anticoipos séricos antileishmânia e durante o acompanhamento nos resultados dos estudos parasitológicos. Sessenta e sete por cento dos pacientes tiveram diagnóstico parasitológico confirmado sendo a inoculação do material de biópsia das lesões em hamsters o método mais sensível. O tempo médio de acompanhamento foi de 12,6 meses. A adesão ao tratamento foi de 100%. Os efeitos colaterais foram dor no local da injeção (86%), proteinúria leve (24%), elevação do nível sérico de creatinina (5%) e perda auditiva subclínica em um dos dois pacientes que realizaram audiometria. Obsevou-se cura clínica em 48% dos pacientes e a percentagem acumulada de recidiva foi de 29% (4/14pacientes) durante o acompanhamento.

Palavras-chaves: Leishmaniose mucosa. Sulfato de aminosidine. Leishmania (Viannia) braziliensis.

------------

ABSTRACT

From September to November 1994, 21 patients with active mucosal leishmaniasis were treated with aminosidine sulphate I6mg/kg/day by intramuscular injection for 20 days. They were principally adult male agricultural workers. Thirteen patients had not received specific treatment and eight had failed to respond to Glucantime® therapy. Diagnosis was based on clinical and epidemiological observations, a search for the parasite, leishmanin skin sensitivity and indirect fluorescent antibody serological tests. Sixty seven percent of patients had Leishmania parasites isolated from inoculated hamsters or visualized in imprints or histopathological sections. The mean follow-up period was 12.6 months. All patients completed treatment. Side effects were pain at the injection site (86%), mild proteinuria (24%), elevated serum creatinine (5%) and subclinical hearing loss in one of two patients who did audiometric tests. Clinical cure was achieved in 48% and the accumulated relapse rate was 29% (4/14).

Keywords: Mucosal leishmaniasis. Aminosidine sulphate. Leishmania (Viannia) braziliensis.

------------

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

REFERÊNCIAS BIBLIOGRÁFICAS

1. Badaró R, Reed SG, Carvalho EM. Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species. The American Journal of Tropical Medicine and Hygiene 32:480-484;1983. [ Links ]

2. Berman JD. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy and future strategies. Reviews of Infectious Diseases 10:560-586;1988. [ Links ]

3. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.Transactions of the Royal Society of Tropical Medicine and Hygiene 84:221- 225; 1990. [ Links ]

4. Correia Filho D. Estudo comparativo entre antimoniato de meglumina, isetionato de pentamidina e sulfato de aminosidine, no tratamento de lesões cutâneas primárias causadas por Leishmania (Viannia) braziliensis L.(V).b. Tese de mestrado, Universidade de Brasília, Brasília, DF, 1993. [ Links ]

5. Franco MA, Barbosa AC, Rath S, Dorea JG. Antimony oxidation states in antileishmanial drugs.The American Journal ofTropical Medicine and Hygiene 52:435-437;1995. [ Links ]

6. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, Llanos-Cuentas A, Berman JD. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Annals of Internal Medicine 113:934-940; 1990. [ Links ]

7. Franke ED, Llanos-Cuentas A, Echevarria JE, Cruz MF, Campos R Tovar AA, Lucas CM, Berman JD. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam®) in the treatment of mucosal leishmaniasis. The American Journal of Tropical Medicine and Hygiene 51:77-82;1994. [ Links ]

8. Grogl M,Thomasin TN, Franke ED. Drug resistance in leishmaniasis: its implications in systemic chemotherapy of cutaneous and mucocutaneous disease. The American Journal of Tropical Medicine and Hygiene 47:117-126;1992. [ Links ]

9. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam#) and review of pertinent clinical studies. The American Journal of Tropical Medicine and Hygiene 46:296-306; 1992. [ Links ]

10. Jones TC Johnson WD, Barreto AC, Lago E, Badaró R, Cerf B, Reed SG, Neto EM, Tada MS, França F. Wiese K, Golightly L, Fikrig E, Costa JML, Cuba CC, Marsden PD. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis.The Journal of Infectious Diseases 156:73-83; 1987. [ Links ]

11. Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paromomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Transactions of the Royal Society of Tropical Medicine and Hygiene 88:92-94; 1994. [ Links ]

12. Magalhães AV Moraes MAP, Raick AN, Llanos- Cuentas A, Costa JML, Cuba CC, Marsden PD. - Histopatologia da leishmaniose tegumentar por Leishmania braziliensis braziliensis. 4. Classificação histopatológica. Revista do Instituto de Medicina Tropical de São Paulo 28:421- 430; 1986. [ Links ]

13. Marsden PD. Pentavalent antimonials: old drugs for new diseases. Revista da Sociedade Brasileira de Medicina Tropical 18:187-198;1985. [ Links ]

14. Marsden PD. Mucosal Leishmaniasis ("espundia" Escomel 1911).Transactions of the Royal Society of Tropical Medicine and Hygiene 80:859- 876:1986. [ Links ]

15. Marsden PD. Mucosal leishmaniais due to Leishmania (Viannia) braziliensis L(V)b in Três Braços, Bahia-Brazil. Revista da Sociedade Brasileira de Medicina Tropical 27:93-101; 1994. [ Links ]

16. Marsden PD, Llanos-Cuentas EA, Lago EL, Cuba CC, Barreto AC, Costa JM, Jones TC. Human mucocutaneous leishmaniasis in Três Braços, Bahia-Brazil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Revista da Sociedade Brasileira de Medicina Tropical 17:179- 186; 1984. [ Links ]

17. Neal RA.The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Annals of Tropical Medicine and Parasitology 62:54-62,-1968. [ Links ]

18. Organización Mundial de la Salud. Lucha contra las leishmaniasis. Serie de Informes Técnicos 793- 176p.Ginebra 1990. [ Links ]

19. Reed SG, Badaró R, Masur H, Carvalho EM, Lorenço R, Lisboa A,Teixeira R, Johnson WD, Jones TC. Selection of a specific skin test antigen for American visceral leishmaniasis. The American Journal ofTropical Medicine and Hygiene 35:79- 85; 1986. [ Links ]

20. Rosa AC, Cuba CC,VexenatA, Barreto AC, Marsden PD. Predominance of Leishmania braziliensis in the regions of Três Braços and Corte de Pedra, Bahia, Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene 82:409-410;1988. [ Links ]

21. Sampaio RNR. Tratamento hospitalar da leishmaniose cutâneo-mucosa. Tese de mestrado, Universidade Federal de Minas Gerais, Belo Horizonte, MG, 1984. [ Links ]

22. Sampaio RNR. Tratamento da forma mucosa de leishmaniose com novo esquema terapêutico com antimonial pentavalente e duas novas drogas: aminosidina e anfotericina B com lipossoma. Tese de doutorado, Universidade de São Paulo, São Paulo, SP, 1993. [ Links ]

23. Schillings RT, Schaffner CP. Differentiation of catenulin-neomycin antibiotics: Identity of catenulin, paromycin hydroximycin and aminosidine. Antimicrobial Agents and Chemotherapy 4:274-285; 1961. [ Links ]

24. Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dosefinding clinical trial. Transactions of the Royal Society ofTropical Medicine and Hygiene 89:219- 223;1995. [ Links ]

Recebido para publicação em 26/01/96.

Endereço para correspondência:

Dr. Gustavo A. Sierra Romero.

Núcleo de Medicina Tropical e Nutrição.

Universidade de Brasília 70919-970. Brasília, DF., CP 04671, Fone: [phone] Fax: [phone].

E- mail: [email protected].